Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 587 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined March 24, 2021 Opioid Use Drops Among Cancer Patients at End of Life August 20, 2021 Dad Sings “Ave Maria” For His Daughter At Disney World April 8, 2019 Exercise of Any Intensity Found to Provide Similar Benefits in Cancer... February 10, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel Coffee Shop Owner Runs Competitor’s Business For Free After Hearing He... FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer Truck Driver Saves People From Bus Fire On Christmas Eve
